Every material Form 8-K PepGen Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PepGen reported a second-quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $23.1 million, or $(0.70) per share, a year earlier, as research and development expenses fell to $12.5 million from $18.4 million. An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study to its 12.5 mg/kg cohort and raising the open-label extension dose from 5 mg/kg to 10 mg/kg. The company had $117.2 million in cash as of June 30, 2026, which it says is enough to fund operations into the fourth quarter of 2027.
Net loss of $17.8 million, or $(0.26) per share, for the quarter ended June 30, 2026, versus $23.1 million, or $(0.70) per share, a year earlier
Research and development expenses were $12.5 million, down from $18.4 million; general and administrative expenses rose to $6.4 million from $5.5 million
Cash, cash equivalents and marketable securities were $117.2 million at June 30, 2026, down from $148.5 million at December 31, 2025
The 10 mg/kg FREEDOM2 cohort data is expected in November 2026, and 12.5 mg/kg cohort results are expected in the first half of 2027
PepGen Inc. updated its corporate presentation on May 21, 2026, ahead of its participation in the 15th International Myotonic Dystrophy Consortium, May 26-30, 2026. The filing contains no new financial results, and it reiterates the company's timelines for clinical data from its FREEDOM2 trial, which the presentation says is subject to a partial clinical hold placed by the U.S. FDA.
Company expects FREEDOM2 10 mg/kg clinical results in 2H 2026 and 12.5 mg/kg clinical results in 2027.
Presentation states cash runway into 2H 2027.
Presentation notes the U.S. FDA recently placed a partial clinical hold on the FREEDOM2 study.
Presentation cites 13 patients enrolled in the FREEDOM-OLE at 5 mg/kg, including 6 from FREEDOM2.
PepGen reported a first quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $30.2 million, or $(0.92) per share, a year earlier, as research and development expenses fell to $13.0 million from $25.4 million. The company also disclosed that the FDA placed a partial clinical hold on its FREEDOM2 study of PGN-EDODM1, which PepGen says relates to previously submitted preclinical studies and has not affected the ongoing trial's timing, and that cash and marketable securities were $132.3 million as of March 31, 2026.
Q1 2026 net loss was $17.8 million, or $(0.26) per share, versus $30.2 million, or $(0.92) per share, in Q1 2025.
Research and development expenses were $13.0 million, compared with $25.4 million a year earlier; general and administrative expenses were $5.9 million in both periods.
The FDA placed a partial clinical hold on the FREEDOM2 study, tied to questions about previously submitted preclinical pharmacology and toxicology studies.
Cash, cash equivalents and marketable securities were $132.3 million at March 31, 2026, down from $148.5 million at December 31, 2025, and PepGen expects this to fund operations into the second half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PepGen Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →